Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study investigates possible beneficial effects of peri-operative treatment (i.e. pre-transplant initiation and prompt post-transplant continuation) with azithromycin in lung transplantation. Our hypothesis is that this therapy will improve early allograft function and outcome following human lung transplantation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitaire Ziekenhuizen Leuven
• Collaborators: Fund for Scientific Research, Flanders, Belgium; Katholieke Universiteit Leuven; KU Leuven
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• Signed informed consent

• Adult (age at least 18 years old at moment of transplantation)

• Single lung transplantation, sequential single (double) lung transplantation or heart-lung transplantation

Exclusion Criteria:

• Known previous allergy for azithromycin (including skin reactions such as rash, urticaria or Stevens- Johnson syndrome, angioneurotic oedema and anaphylaxis)

• Retransplantation or multi-organ (other than heart-lung) transplantation

• Inclusion in Transmedics® Organ Care System (OCS™ LUNG) study (OCS-LUN-03-2010)(S53795).